Redbiotec raises €8.5M Series A round
1 May 2020· Schlieren, Switzerland· health, biotech, synthetic_biology, food, b2b
The company raised 9M CHF in Series A funding to focus on the HSV-2 vaccine program and take the most advanced asset into Phase I/IIa clinical trial.
About Redbiotec
Stage
Series A
Headquarters
Schlieren, Switzerland
Founded
2006
Team Size
6–20
Sectors
healthbiotechsynthetic_biologyfoodb2b